• Satellos completed enrollment for BASECAMP, a Phase 2 trial of forazapadin in Duchenne muscular dystrophy.
• No results have been presented; topline clinical data are now expected in the first quarter of 2027.
• Readout timing was pushed back to compile a more complete dataset for potential FDA discussions on an accelerated development path.
• The study is designed to assess safety, tolerability, muscle strength, and broader signs of functional benefit and muscle regeneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836402) on September 30, 2026, and is solely responsible for the information contained therein.